Advertisement

Topics

Visterra, Inc. Company Profile

06:33 EDT 23rd September 2018 | BioPortfolio

Visterra discovers and develops novel drugs for the prevention and treatment of major diseases. The company’s proprietary platform generates unique structural information that identifies novel drug target sites and guides the design of drugs to effectively combat disease. The company’s lead product candidate, VIS410, is a broad spectrum monoclonal antibody for the prevention and treatment of both seasonal and pandemic influenza. The company is building a proprietary pipeline in infectious disease, and continuing to expand its disease area focus through strategic partnerships in infectious and other diseases. Visterra was founded by Dr. Ram Sasisekharan of MIT and is backed by Polaris Venture Partners, Flagship Ventures, and Lux Capital. For more information please visit www.visterrainc.com.


News Articles [23 Associated News Articles listed on BioPortfolio]

Otsuka to Expand its Pipeline of Antibody-Based Therapies through its $430 Million Acquisition of Visterra

TOKYO & WALTHAM, Mass.–(BUSINESS WIRE)–Otsuka Pharmaceutical Co., Ltd. (Otsuka) and Visterra, Inc. (Visterra) announce that they have entered into a definitive merger agreement pursuan...

Otsuka Ramps Up Its Antibody Game with $430M Visterra Acquisition

Otsuka Pharmaceutical is expanding its pipeline and U.S. reach with an agreement to acquire Waltham, MA, clinical-stage drug developer Visterra for $430 million in cash. The deal, announced Wednesday,...

Otsuka Pharmaceutical agrees to purchase Visterra for $430m

Japan-based Otsuka Pharmaceutical has signed a definitive merger agreement to acquire US-based biotechnology company Visterra for a cash consideration of...Read More... The post Otsuka Pharmaceutical ...

Otsuka snaps up Visterra in $430 million deal

Otsuka Pharmaceutical has announced it has reached a definitive, board-approved agreement with Visterra to acquire the latter company in an all-cash transaction to the value of $430 million. read more

Otsuka buys Visterra for $430mm in cash

Otsuka Pharmaceutical Co. Ltd. agreed to pay $430mm in cash to acquire Visterra Inc., a privately held company developing antibody therapeutics for hard-to-treat diseases.

Otsuka Pharmaceuticals Buying Visterra for $430 Million

Otsuka Pharmaceutical, based in Tokyo, Japan, is acquiring Waltham, Massachusetts-based Visterra for $430 million in cash. The deal is expected to close in the third quarter of this year.

Antibody developer Visterra to be purchased by Otsuka

Antibody developer Visterra will be acquired by Otsuka Pharmaceutical for $430 million cash, giving the buyer programs based  -More- 

Otsuka Bags Novel Antibody Tech, Pipeline In $430m Visterra Buy

Otsuka liked the private US antibody tech company Visterra so much that it is buying it, in a move developing...   

Drugs and Medications [0 Results]

None

PubMed Articles [0 Results]

None

Clinical Trials [0 Results]

None

Companies [2 Associated Companies listed on BioPortfolio]

Visterra, Inc.

Visterra discovers and develops novel drugs for the prevention and treatment of major diseases. The company’s proprietary platform generates unique structural information tha...

Visterra Inc.

Visterra discovers and develops novel drugs for the prevention and treatment of major diseases. The company’s proprietary platform generates unique structural information tha...

More Information about "Visterra, Inc." on BioPortfolio

We have published hundreds of Visterra, Inc. news stories on BioPortfolio along with dozens of Visterra, Inc. Clinical Trials and PubMed Articles about Visterra, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Visterra, Inc. Companies in our database. You can also find out about relevant Visterra, Inc. Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Swine Flu - H1N1 influenza - H7N9
Swine flu is the common name given to a relatively new strain of influenza (flu) that caused a flu pandemic in 2009-2010. It is also referred to as H1N1 influenza (because it is the H1N1 strain of virus). The H1N1 flu virus will be one of the main vi...

Infectious-diseases
Antiretroviral Therapy Clostridium Difficile Ebola HIV & AIDS Infectious Diseases Influenza Malaria Measles Sepsis Swine Flu Tropical Medicine Tuberculosis Infectious diseases are caused by pathogenic...


Corporate Database Quicklinks



Searches Linking to this Company Record